Literature DB >> 8027104

In vivo induction of macrophage Ia antigen (MHC class II) expression by biomedical polymers in the cage implant system.

O Petillo1, G Peluso, L Ambrosio, L Nicolais, W J Kao, J M Anderson.   

Abstract

Examination of the cellular components in the inflammatory exudate, which infiltrates subcutaneous cages, can be used to monitor the progress of an inflammatory response to an implanted material. Of particular interest is the study of monocyte/macrophage infiltration into the implanted cages containing biomaterials, as macrophages may initiate a wide spectrum of responses upon interaction with a foreign material. In this study, the authors propose a technique using subcutaneous tissue cages in conjunction with cytofluorimetric analysis of exudate leukocytes to evaluate the monocyte/macrophage cell activation in response to different materials. The studies reported here used several materials (thermoplastic and elastomeric polymers) as the challenging agent, to demonstrate whether polymers, chemically different from each other, could differentially activate macrophages to carry out their proinflammatory role more effectively. The materials tested included: poly(etherurethane ureas) (PEUU A'), poly(etherurethane ureas) with a surface active additive, Methacrol, (PEUU C'), polymethylsiloxane (PDMS), polyetherimide, (PEI), and polyetheretherketone, (PEEK). For all tested materials, the maximum numbers of exudate cells and of Ia-positive macrophages were found on day 7, although the entity of the cell increase was associated with the material used for the implant. Similarly, the percentage of Ia-positive macrophages varied according to the specific polymer present in the cages after 7 days. By day 14, the percentage of Ia-positive macrophages decreased with individual exudates showing 19-32% Ia-positive cells depending on the different type of material. Only in the case of PDMS did the percentage of Ia-positive macrophages remain the same as compared with control empty cage macrophages.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027104     DOI: 10.1002/jbm.820280514

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  7 in total

1.  Hemocompatibility of poly(ether imide) membranes functionalized with carboxylic groups.

Authors:  R Tzoneva; B Seifert; W Albrecht; K Richau; T Groth; A Lendlein
Journal:  J Mater Sci Mater Med       Date:  2008-05-02       Impact factor: 3.896

2.  Response to polyetherimide based composite materials implanted in muscle and in bone.

Authors:  A Merolli; V Perrone; P Tranquilli Leali; L Ambrosio; R De Santis; L Nicolais; C Gabbi
Journal:  J Mater Sci Mater Med       Date:  1999-05       Impact factor: 3.896

3.  In vivo cytokine-associated responses to biomaterials.

Authors:  Robert J Schutte; Lola Xie; Bruce Klitzman; William M Reichert
Journal:  Biomaterials       Date:  2008-10-11       Impact factor: 12.479

Review 4.  PEEK biomaterials in trauma, orthopedic, and spinal implants.

Authors:  Steven M Kurtz; John N Devine
Journal:  Biomaterials       Date:  2007-08-07       Impact factor: 12.479

5.  Sustained Subconjunctival Delivery of Infliximab Protects the Cornea and Retina Following Alkali Burn to the Eye.

Authors:  Chengxin Zhou; Marie-Claude Robert; Vassiliki Kapoulea; Fengyang Lei; Anna M Stagner; Frederick A Jakobiec; Claes H Dohlman; Eleftherios I Paschalis
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-01-01       Impact factor: 4.799

6.  Strategy for Controlling the Properties of Bioactive Poly-Ether-Ether-Ketone/Hydroxyapatite Composites for Bone Tissue Engineering Scaffolds.

Authors:  Gaoyan Zhong; Mohammad Vaezi; Xinliang Mei; Ping Liu; Shoufeng Yang
Journal:  ACS Omega       Date:  2019-11-05

7.  Microporous Drug Delivery System for Sustained Anti-VEGF Delivery to the Eye.

Authors:  Chengxin Zhou; Arushi Singh; Grace Qian; Natalie Wolkow; Claes H Dohlman; Demetrios G Vavvas; James Chodosh; Eleftherios I Paschalis
Journal:  Transl Vis Sci Technol       Date:  2020-07-02       Impact factor: 3.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.